The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder

Thrombosis and Haemostasis

Volumn 99, Issue 6, 2008, Pages 1119-1120

  Bellucci, Sylvia ^a,b   Cassinat, Bruno ^c   Bonnin, Nadine ^c   Marzac, Christophe ^d   Crassard, Isabelle ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; BRAIN VEIN; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; HEMATOCRIT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PHLEBOGRAPHY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACRANIAL THROMBOSIS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 44949215627     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-02-0081     Document Type: Letter

References (12)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466.
2. Gruppo Italiano Studio Policitemia. Polycythemia Vera: the natural history of 1213 patients follow up for 20 years. Ann Int Med 1995; 123: 656-664
3. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-543.
4. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-170.
5. Tefferi A, Elliott M.Thrombosis in myeloproliferative disorders : prevalence, prognostic factors and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320
6. Campbell PJ, Scott LM, Buck G, et al. and the United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
7. Randi ML, Lombardi AM, Scapin M, et al. Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders. Thromb Haemost 2007; 98: 702-704.
8. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007 ; 5: 55-61.
9. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
10. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
11. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-2040.
12. Ferro JM, Canhão P, Stam J, et al. and the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670.